Is It Safe to Take Ritonavir and Simvastatin Together?

No. According to FDA drug labeling, ritonavir and simvastatin are contraindicated—meaning they should not be used together. The combination carries a serious risk of muscle injury, specifically myopathy and rhabdomyolysis. If you take both drugs, you should speak with your doctor or pharmacist immediately about switching to a different statin or reconsidering your treatment plan.

What the Source Says

The interaction record is drawn directly from the FDA-approved drug label for simvastatin. The label classifies this as a contraindicated interaction, assigning the highest severity level. The specific concern is that ritonavir may increase simvastatin concentrations in the bloodstream, raising the risk of myopathy (muscle disease or damage) and rhabdomyolysis (severe muscle breakdown that can lead to acute kidney injury and death).

The source record groups simvastatin with other statins (lovastatin, atorvastatin, and rosuvastatin) and notes that ritonavir is a protease inhibitor—a class of antiretroviral drugs used primarily to treat HIV. The label specifically warns that the potential for myopathy, including rhabdomyolysis, is the basis for the contraindication.

Important note on mechanism: The source record does not specify the exact mechanism by which ritonavir increases simvastatin concentration. However, general pharmacology knowledge—explained below—can help you understand why this interaction is plausible and why FDA labeling reflects this concern.

How to Understand This

What Is Myopathy and Rhabdomyolysis?

Myopathy is a general term for disease or dysfunction of muscle tissue. Rhabdomyolysis is a severe form in which muscle fibers break down rapidly, releasing their contents—particularly a protein called myoglobin—into the bloodstream. This can overwhelm the kidneys, causing acute kidney injury. Both conditions can cause muscle pain, weakness, and dark urine. Rhabdomyolysis is a medical emergency.

What Are Simvastatin and Ritonavir?

Simvastatin is an HMG-CoA reductase inhibitor, commonly called a statin. Statins lower cholesterol by blocking an enzyme in the liver that produces cholesterol. Simvastatin is widely prescribed for cardiovascular disease prevention. Like all statins, it is metabolized (broken down) in the liver, primarily by an enzyme system called the cytochrome P450 pathway.

Ritonavir is a protease inhibitor antiretroviral drug used to treat HIV. In modern HIV therapy, ritonavir is often used at low doses not for its direct antiviral effect, but as a pharmacokinetic booster—meaning it slows the metabolism of other drugs in the protease inhibitor class, allowing them to reach higher, more therapeutic concentrations. Ritonavir is a potent inhibitor of several cytochrome P450 enzymes, particularly CYP3A4.

Why the Interaction Matters: General Pharmacology Background

Simvastatin undergoes extensive hepatic metabolism. When a potent enzyme inhibitor like ritonavir is present, simvastatin's clearance from the body is substantially reduced. This means simvastatin levels in the bloodstream can rise significantly—sometimes several-fold higher than intended. Higher statin concentrations increase the risk of statin-related muscle injury across the spectrum from mild myalgia (muscle ache) to severe rhabdomyolysis.

This is not a theoretical concern: elevated statin concentrations are a well-recognized dose-dependent risk factor for myopathy. Even at standard doses, simvastatin carries a documented risk of muscle-related adverse events; adding a CYP3A4 inhibitor amplifies this risk substantially.

Note: The source record itself does not specify CYP3A4 inhibition as the mechanism. The mechanism explanation above reflects established general pharmacology, not the supplied interaction record. The key source-supported fact is that ritonavir increases simvastatin concentration and that this increase raises the risk of myopathy and rhabdomyolysis.

Who Should Pay Particular Attention

Anyone currently taking both ritonavir and simvastatin should notify their healthcare provider or pharmacist right away. This is especially important for:

• Patients with HIV who are on protease inhibitor–based therapy and have been prescribed simvastatin for cholesterol management
• People with a personal or family history of statin-induced muscle injury
• Those taking other medications that also inhibit CYP3A4 (which could compound the risk)
• Patients with renal (kidney) impairment, since the kidneys are involved in clearing some statin metabolites and are at risk in rhabdomyolysis

That said, the contraindication applies broadly: the FDA labeling does not carve out specific subgroups as "safe"—the combination is listed as contraindicated for all patients.

Hypothetical Examples

Example 1: A Patient Newly Diagnosed With HIV

This is a hypothetical scenario illustrating the documented interaction facts.

An adult patient with newly diagnosed HIV is started on an antiretroviral regimen that includes ritonavir as a protease inhibitor booster. At the same time, the patient has elevated cholesterol and is prescribed simvastatin for cardiovascular risk reduction. Within a few weeks, the patient develops unexplained muscle pain and weakness, and blood tests show elevated muscle enzymes (creatine kinase, or CK). In this scenario, the contraindicated interaction between ritonavir and simvastatin could be the cause: ritonavir has reduced simvastatin's clearance, raising blood levels of the drug and triggering statin myopathy. The prescriber should have identified this contraindication at the time of HIV therapy initiation and recommended an alternative statin or a non-statin lipid-lowering agent.

Example 2: Switching Antiretroviral Therapy

This is a hypothetical scenario illustrating the documented interaction facts.

A patient taking ritonavir-boosted protease inhibitor therapy and simvastatin together is found to have a ritonavir-resistant HIV strain and is switched to a different antiretroviral class (e.g., an integrase inhibitor) that does not interact with statins. Once ritonavir is discontinued, simvastatin concentrations would be expected to return to normal levels, reducing the risk of myopathy. This illustrates why stopping one of the two drugs (or switching one of them) is the appropriate management approach to this contraindication.

What to Discuss With a Pharmacist or Physician

If you take ritonavir and simvastatin, or if you are about to be prescribed one while already taking the other, bring this interaction to the attention of your doctor and pharmacist. Here are some source-grounded questions and considerations to raise:

• Is there an alternative statin? The FDA label mentions other statins (lovastatin, atorvastatin, rosuvastatin) in the contraindication list, but different statins may carry different interaction risks. Ask your provider whether a different lipid-lowering agent is appropriate for your situation.
• Is the ritonavir dose essential? In some HIV treatment regimens, ritonavir is used as a booster at a low dose. Ask whether the regimen can be changed to an antiretroviral that does not require ritonavir.
• Do I have symptoms of myopathy? Discuss any unexplained muscle pain, weakness, dark urine, or fatigue with your provider. These could signal statin myopathy.
• What is my baseline muscle status? Ask whether baseline creatine kinase (muscle enzyme) testing is appropriate, especially if you have been on both drugs for some time.
• What non-statin options exist? If a statin is medically necessary but ritonavir cannot be changed, ask about non-statin lipid-modifying therapies, such as ezetimibe, PCSK9 inhibitors, or bempedoic acid.

These are questions to explore with your healthcare team—not instructions to change your medication on your own. Your doctor and pharmacist know your full medical history and can weigh the risks and benefits specific to your situation.

Key Takeaways

• Ritonavir and simvastatin are contraindicated according to FDA drug labeling—they should not be used together.
• The primary concern is myopathy and rhabdomyolysis (serious muscle breakdown), which can result from elevated simvastatin concentrations in the bloodstream.
• Ritonavir is a potent inhibitor of drug metabolism, which can substantially raise simvastatin levels; the source record does not specify the exact mechanism but identifies this concentration increase as the basis for the contraindication.
• If you are taking both drugs, contact your pharmacist or doctor immediately to discuss alternatives—either a different statin, a different antiretroviral regimen, or a non-statin lipid-lowering therapy.
• Do not stop either medication on your own; let your healthcare team guide the change to avoid any adverse effects from abrupt discontinuation.

Sources

• DailyMed: FDA-Approved Drug Labels (search for simvastatin to access the complete FDA label including contraindications)
• Open FDA: Drug Information (searchable database of FDA-approved medications and labeling)
• RxNorm: Normalized Naming System for Clinical Drugs (maintained by the National Library of Medicine; useful for verifying drug names and identifiers)
• PubMed Central (for peer-reviewed literature on statin safety and drug interactions)

If you take ritonavir, simvastatin, or both, use checkdruginteractions.com to review your complete medication profile and identify potential interactions. Always discuss any changes to your medications with your pharmacist or physician before making adjustments. This article explains a documented interaction based on FDA source material; it is not a substitute for personalized medical or pharmacological advice.